Publications » Antimicrobial stewardship, rapid PCR and STI

12/01/2021Publication

Antimicrobial stewardship, rapid PCR and STI

Significant improvement to patient care and antimicrobial stewardship with appropriate use of antibiotics may be achieved through the use of rapid point-of-care PCR STI testing.

Antimicrobial stewardship, rapid PCR and STI

Challenge

Accurate same-day sexually transmitted infections (STI) diagnostic test results are generally unavailable, leading to syndromic management with high rates of over- and under-treatment, which contributes to antibiotic resistance.
Hypothesis: Might a rapid molecular diagnostic test help clinicians deliver the right treatment to women with STI during a single visit?

Action

Conduct a cross-sectional single-visit study to evaluate the Visby Medical Sexual Health Click Test with respect to:

  • Ease of integration into clinical practice,
  • Acceptance by patients and clinic personnel, and
  • Potential to inform correct treatment decisions.

Result

  1. If integrated efficiently into the clinical workflow, the test would have minimal impact on staff time and visit duration for patients.
  2. Patients strongly agreed that self-collecting the vaginal swab was easy, and they were comfortable waiting up to 30-minutes to get results. Operators reported the device was easy to use. Clinicians valued the rapid results.
  3. Importantly, in 13 of 15 undertreated cases, the Visby Medical test correctly identified the causative pathogen. The test also correctly identified all 33 incidences of over-treatment. This suggests that clinical adoption of the Visby Medical test into primary care clinics could reduce over- and under-treatment of STIs, contributing to improved antimicrobial stewardship.

In addition, the following were observed:

  • Reduced test turnaround time (TAT) from an average of 6 days for Standard of Care (SOC) down to ± 45 minutes for Visby Medical Sexual Health Click test
  • Potential to reduce antibiotic overuse and associated effects on emerging antibiotic-resistant bacteria
  • Potential to reduce delays in correctly identifying infected individuals by delivering test results in a single visit
  • Improved physician and patient satisfaction

Conclusion

The biggest potential benefit of using a point of care molecular / polymerase chain reaction (PCR) test was the rapid turnaround time for delivery of the test results in a single visit. This would allow clinicians to treat patients based on the test results as opposed to empiric (presumptive) treatment, thereby reducing over- and under- treatment and reduced misuse of antibiotics.

Rate of patients over- or under-treated 

Rate of patients over- or under-treated

Test TAT

Test Turnaround Time

 

See the full article here.

Read more articles & insights

04/05/2024Viewpoint

The Case for PCR at the Point of Care: Reshaping STI Testing in Urgent Care Clinics

In light of the rising rates of sexually transmitted infections (STIs), urgent care clinics have found themselves at a crucial crossroads. PCR (Polymerase Chain Reaction) testing at the point of care emerges as a potential game-changer.

Read More
The Case for PCR at the Point of Care: Reshaping STI Testing in Urgent Care Clinics

03/14/2024Viewpoint

Understanding the Financial Impact of PCR Point of Care Testing for STIs

The adoption of point-of-care polymerase chain reaction (PCR) testing represents a significant leap forward in diagnostic capabilities. With its promise of speed, accuracy, and efficiency, PCR testing technology is setting a new standard in patient care.

Read More
Understanding the Financial Impact of PCR Point of Care Testing for STIs

03/07/2024Viewpoint

5 Frequently Asked Questions on Implementing PCR into Urgent Care

The adoption of point-of-care polymerase chain reaction (PCR) testing represents a significant leap forward in diagnostic capabilities. With its promise of speed, accuracy, and efficiency, PCR testing technology is setting a new standard in patient care.

Read More
5 Frequently Asked Questions on Implementing PCR into Urgent Care

02/21/2024Press Release

CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test

The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today that it will award biotechnology company Visby Medical of San Jose, California, up to $1.8 million to develop a portable polymerase chain reaction (PCR) test that can detect gonorrhea and assess its susceptibility to ciprofloxacin.

Read More
CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test